Nkarta (NKTX) Preferred Stock Liabilities (2019 - 2020)
Nkarta (NKTX) posted quarterly Preferred Stock Liabilities of $59.8 million for Q2 2020, up 361.18% year-over-year from $13.0 million in Q3 2019, and little changed quarter-over-quarter from $59.8 million in Q1 2020.
Nkarta (NKTX) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Nkarta's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $59.8 million for Q2 2020.
- In Q2 2020, Preferred Stock Liabilities rose 361.18% year-over-year to $59.8 million; the TTM figure through Jun 2020 stood at $59.8 million (up 361.18% YoY), while the FY2019 annual figure was $59.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2020 stood at $59.8 million, roughly flat from $59.8 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $59.8 million in Q4 2019, with the low at $13.0 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 59.82 Mn |
| Mar 31, 2020 | 59.82 Mn |
| Dec 31, 2019 | 59.82 Mn |
| Sep 30, 2019 | 54.36 Mn |
| Jun 30, 2019 | 12.97 Mn |